title: Prostate magnetic resonance imaging at 3 Tesla: Is administration of hyoscine-N-butyl-bromide mandatory?
abstract: OBJECTIVE
  To evaluate the value of administration of hyoscine-N-butyl-bromide (HBB) for image quality magnetic resonance imaging (MRI) of the prostate.
  
  
  METHODS
  Seventy patients were retrospectively included in the study. Thirty-five patients were examined with administration of 40 milligrams of HBB (Buscopan(®); Boehringer, Ingelheim, Germany); 35 patients were examined without HBB. A multiparametric MRI protocol was performed on a 3.0 Tesla scanner without using an endorectal coil. The following criteria were evaluated independently by two experienced radiologists on a five-point Likert scale: anatomical details (delineation between peripheral and transitional zone of the prostate, visualisation of the capsule, depiction of the neurovascular bundles); visualisation of lymph nodes; motion related artefacts; and overall image quality.
  
  
  RESULTS
  Comparison of anatomical details between the two cohorts showed no statistically significant difference (3.9 ± 0.7 vs 4.0 ± 0.9, P = 0.54, and 3.8 ± 0.7 vs 4.2 ± 0.6, P = 0.07) for both readers. There was no significant advantage regarding depiction of local and iliac lymph nodes (3.9 ± 0.6 vs 4.2 ± 0.6, P = 0.07, and 3.8 ± 0.9 vs 4.1 ± 0.8, P = 0.19). Motion artefacts were rated as "none" to "few" in both groups and showed no statistical difference (2.3 ± 1.0 vs 1.9 ± 0.9, P = 0.19, and 2.3 ± 1.1 vs 1.9 ± 0.7, P = 0.22). Overall image quality was rated "good" in average for both cohorts without significant difference (4.0 ± 0.6 vs 4.0 ± 0.9, P = 0.78, and 3.8 ± 0.8 vs 4.2 ± 0.6, P = 0.09).
  
  
  CONCLUSIONS
  The results demonstrated no significant effect of HBB administration on image quality. The study suggests that use of HBB is not mandatory for MRI of the prostate at 3.0 Tesla.
authors.affiliation: Matthias C Roethke, Alexander Radbruch, Heinz-Peter Schlemmer, Department of Radiology, German Cancer Research Center Heidelberg (DKFZ), 69120 Heidelberg, Germany.
authors.forename: Matthias C
authors.initials: MC
authors.lastname: Roethke
authors.forename: Timur H
authors.initials: TH
authors.lastname: Kuru
authors.forename: Alexander
authors.initials: A
authors.lastname: Radbruch
authors.forename: Boris
authors.initials: B
authors.lastname: Hadaschik
authors.forename: Heinz-Peter
authors.initials: HP
authors.lastname: Schlemmer
keywords: 3 Tesla; Buscopan; Butylscopolamine; Magnetic resonance imaging; Motion artefacts; Prostate cancer
references.citation: Clin Radiol. 2007 Nov;62(11):1087-93
references.pmid: 17920868
references.citation: Acad Radiol. 2004 Aug;11(8):857-62
references.pmid: 15354305
references.citation: J Comput Assist Tomogr. 2008 Mar-Apr;32(2):163-72
references.pmid: 18379296
references.citation: Eur Radiol. 2012 Apr;22(4):746-57
references.pmid: 22322308
references.citation: Eur Urol. 2009 Apr;55(4):801-14
references.pmid: 19185981
references.citation: Radiology. 2005 Feb;234(2):576-81
references.pmid: 15616117
references.citation: Clin Radiol. 2010 Jun;65(6):460-4
references.pmid: 20451013
references.citation: J Comput Assist Tomogr. 2006 May-Jun;30(3):355-61
references.pmid: 16778606
references.citation: Acta Radiol. 2011 Jun 1;52(5):575-80
references.pmid: 21498291
references.citation: Acta Radiol. 2009 Jun;50(5):562-9
references.pmid: 19455449
references.citation: Acad Radiol. 2004 Aug;11(8):863-7
references.pmid: 15288036
references.citation: Radiology. 2007 Jul;244(1):184-95
references.pmid: 17495178
references.citation: J Comput Assist Tomogr. 2007 Jul-Aug;31(4):534-8
references.pmid: 17882027
references.citation: J Urol. 2010 Feb;183(2):520-7
references.pmid: 20006859
references.citation: Eur Radiol. 2003 Feb;13(2):294-8
references.pmid: 12598993
references.citation: Clin Radiol. 2008 Jul;63(7):739-43
references.pmid: 18555031
references.citation: AJR Am J Roentgenol. 1988 Mar;150(3):513-22
references.pmid: 3257601